.png)
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new partnerships, raise new funding, receive FDA clearance, and much more on the road to LSI Europe ‘24 in Sintra, Portugal (Sept 16-20).
Announced a strategic partnership with Capstone Health Alliance. This collaboration will extend access to Access Vascular’s MIMIX hydrophilic catheters for Capstone’s network of 300+ hospitals, independent health systems, and physician practices across the US.
Secured a two-year $485K Phase I Small Business Innovation Research (SBIR) grant from the NIH for the continued development of a novel paddle-type epidural stimulation lead. BackStop Neural is developing a spinal cord system with a nove lead featuring thin-film electrodes encapsulated with a softening polymer.
Achieved FDA listing as a Class II 510(k) Exempt Device for its flagship product, 3DGait. The device leverages a single camera and 3D AI technology to analyze human body motion, offering insights into movement patterns and related disorders.
Presented 36-month follow-up data on a novel Cilioscleral Interpositioning Device, IntercilⓇ Uveal Spacer, for treating glaucoma. The results show sustained intraocular pressure control of 8.0 mmHg with a mean pressure reduction of 33% compared to baseline and a 70% reduction in medication dependence.
Secured €5.7M in the first close of its Series A funding round. The funds will be used to initiate the US regulatory approval process for the first version of its microwave ablation platform and commence its clinical trials.
Appointed LSI Alumni Sascha Berger as Investment Director for Biotech, and will lead and shape NEOM’s global biotech and medtech investment strategy. NEOM is a large Saudi Arabia-based project that aims to be a hub for technological innovation and sustainable living.
Received a $1.1M Christopher & Dana Reeve Foundation grant to expand its brain-computer interface (BCI) study. The study evaluates the use of BCI to restore thought-driven use of the hands and arms after spinal cord injury.
Obtained French Health Authority approval to initiate its feasibility clinical study in Post-Cardiac Arrest Syndrome. ORIXHA is developing the Vent2Cool medical device to almost immediately protect the vital organs, in particular the brain and heart, of patients resuscitated after cardiac arrest and thus significantly reduce mortality and morbidity.
Passed its ISO 13485 Stage 1 certification audit. Panda Surgical is developing a next-generation handheld robotics platform that offers neurosurgeons enhanced dexterity and control in confined spaces, enabling more surgeons to perform complex, minimally invasive procedures.
Appointed Chad Hoskins as CEO following the recent close of $42M Series D funding. The company’s product, PhagenyxⓇ Neurostimulation System, utilizes pharyngeal electrical stimulation to restore swallowing control, facilitate airway protection, and accelerate recovery in patients with acute dysphagia.
Secured £343,000 from Innovate UK's Cancer Therapeutics program. The company is developing an implantable electric field therapy treatment for aggressive brain tumors, with an initial focus on glioblastoma.
Appointed Maurizio Taramasso to its Scientific Advisory Board. The company is developing a minimally invasive transcatheter device that replicates the repair concept of the Clover open-heart technique to treat tricuspid valve regurgitation.
Announced that its TMINI® Miniature Robotic System has received FDA 510(k) clearance for use with Zimmer Biomet’s PersonaⓇ Personalized KneeⓇ system. The TMINI® Miniature Robotic System is designed to enable accurate implant placement.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
.png)
